Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab Dose-Ranging Study in Asian RA Patients
NCT01463059Phase 2Completed
- Sponsor
- UCB
- Start
- Oct 2011
- Primary completion
- Feb 2013
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of olokizumab in rheumatoid arthritis (RA) (6 arms), sponsored by UCB. Primary endpoint: Disease Activity Score 28-joint count (C-reactive protein) at 12 weeks. Started Oct 2011; status: completed.
02
Drugs
olokizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01463059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01463059.